Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGB101 in Healthy Older Adults
NCT03461861Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levetiracetam in Alzheimer's disease (AD) (2 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Functional Connectivity Strengths of Neural Networks at 2 weeks. Started Apr 2019; status: completed.
02
Drugs
levetiracetam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03461861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03461861.